Avatrombopag (AKR-501,E5501,YM477) is an orally available thrombopoietin receptor (c-Mpl) agonist that increases platelet count but does not activate platelets.

 

Brand: BCM

 

Target: Thrombin; Thrombopoietin Receptor

 

Signaling Pathways: Immunology/Inflammation; Proteases/Proteasome

 

In Vivo: Avatrombopag is treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure

 

pKa: 3.04±0.70(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS05

 

Isomeric SMILES: C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl  

 

InChIKey: OFZJKCQENFPZBH-UHFFFAOYSA-N  

 

InChI: InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38) 

 

Attribute
[Chem Name]	1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid
[Synonym]	Avatrombopag; AKR-501; E5501; YM477
[CAS No.]	570406-98-3
[EINECS]	1312995-182-4
[MDL No.]	MFCD18633249
[Formula]	C29H34Cl2N6O3S2
[Molecular]	649.65
[Form]	A crystalline solid
[Storage]	Sealed in dry. Store in freezer, under -20°C

Goods Tag